A multicenter randomized controlled trial comparing the efficacy and safety of lamivudine-adefovir combinational therapy with adefovir monotherapy for chronic hepatitis B and cirrhosis with lamivudine-resistance. - Adefovir monotherapy for lamivudine-resistant chronic hepatitis B and cirrhosis

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences0 sites100 target enrollmentAugust 1, 2007

ConditionsChronic hepatitis B or cirrhosis with lamivudine-resistance

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Chronic hepatitis B or cirrhosis with lamivudine-resistance
Sponsor: Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Enrollment: 100
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

August 1, 2007

End Date

December 1, 2011

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•(1\) The patients who has a history of an allergy against nucleos(t)ide analogues(2\) The patients who have received interferon within 6 months before registration.(3\) Pregnant women, or women who are nursing(4\) The patients with an uncontrollable heart trouble (myocardial infarction, heart failure, or arrhythmia)(5\) The patients with severe chronic renal failure or chronic respiratory failure(6\) The patients with other chronic liver disease, such as autoimmune hepatitis, primary biliary cirrhosis, alcoholic hepatitis, or chronic hepatitis C.(7\) The patients who were thought to be inapproriate for this study by the doctor